Inscopix Expands Cloud-Based IDEAS Platform for Individual Lab Use

The IDEAS Platform offers individual labs a first-of-its-kind, cloud-based solution to organizing, analyzing and sharing brain imaging data at scale.

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–#IDEAS–Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it is expanding the market availability for its Inscopix Data Exploration, Analysis and Sharing (IDEAS) Platform to include individual labs, which allows academic researchers to vastly improve how they share, analyze and organize neuroscience data.

Initially launched in December 2021 as enterprise-friendly solution and then showcased at FENS Forum 2022 with the workflow for analyzing neural circuit modulation, the cloud-based IDEAS Platform is the first-of-its-kind turnkey solution for processing multimodal preclinical research data with its powerful, intuitive database solution and scalable compute infrastructure. Addressing one of the major roadblocks in current brain research efforts, IDEAS supports the organization, multi-modal integration, analysis and sharing of neuroscience imaging data and methods to accelerate basic research and catalyze progress towards the next-generation of neurotherapeutics.

“With the miniscope platform and other novel brain mapping tools, we now live in the age of big brain data, and the IDEAS Platform is the first integrated, multi-modal solution to address the needs of managing and analyzing brain data at scale,” said Kunal Ghosh, Ph.D., founder and CEO at Inscopix.

The IDEAS Platform comes with several processing and analysis workflows ready to use — simplifying post-experiment data handling and making it so researchers in any lab can efficiently organize, analyze and share results without relying on other tools. Workflows can be queued and batch executed, enabling analysis of rich multimodal datasets at scale without software or hardware requirements.

“The use of multiple data-rich technologies in the modern neuroscience lab also brings challenges like the siloed and cumbersome storage of data, lack of collaborative tools and the absence of readily shared and reproducible analysis methods,” said David Gray, Ph.D., CSO at Inscopix. “The new IDEAS Platform is an integrated, user-friendly solution that overcomes these challenges, and we’re now excited to offer it to both enterprise and individual research labs.”

Inscopix at Neuroscience 2022

The IDEAS Platform, along with other innovations around the company’s miniature microscope-based brain mapping platforms, will be featured at Neuroscience 2022 being held in San Diego, California, Nov 12-16. The Inscopix showcase at the meeting will highlight key product and applications updates, including:

The Inscopix booth will have scheduled demonstrations of the IDEAS Platform, sign-ups for which are currently open here. The nVision System, first announced in July 2022, will be on display at the booth for the first time.

The company is also offering the opportunity to book a 1:1 consultation here with the company’s expert scientists to see any and all of the products and applications in person while at the meeting. Inscopix will provide details of abstracts throughout the meeting via Twitter at @inscopix.

Presentations by Inscopix include:

  • Tools for acquisition and analysis of simultaneous neural activity and vascular dynamics in freely behaving animals

    D. Ollerenshaw et al., Ph.D.

    Session 577 – Optical Methodology: Application

    Nov. 15, 2022 1:00 PM – 2:00 PM (PT)
  • Prefrontal cortex neuronal hyperactivity in a mouse model of Alzheimer’s beta-amyloidosis

    S. Huang et al., Ph.D.

    Session 120 – Alzheimer’s Disease: Biomarkers II

    Nov. 13, 2022 9:00 AM – 10:00 AM (PT)

Meeting attendees can visit Inscopix at booth #1028, or email sales@inscopix.com to schedule a conversation with a member of the company.

About Inscopix, Inc.

Inscopix is a brain imaging platform company focused on decoding the mind to better understand and address all neurological disorders. We are solving perhaps the greatest unmet need in humanity – understanding how the brain works – and leveraging that knowledge to develop effective neurological treatments. With almost 200 peer-reviewed publications validating our innovative brain circuitry imaging technology, Inscopix is empowering the neuroscience research community to advance science while bringing a new generation of transformational therapeutics to patients with difficult-to-treat brain disorders. Learn more at inscopix.com and follow us @inscopix.

Contacts

Inscopix Contact:
Martin Verhoef

mverhoef@inscopix.com
650-200-7244

Media Contact:
Tim Ingersoll

tim@bioscribe.com

error: Content is protected !!